ライフサイエンスコーパス: structure-activity relationship

1 idal inhibitors as well as to disclose their structure-activity relationship.

2 s, rationally improve understanding of their structure-activity relationship.

3 em, with a very interesting and well-defined structure-activity relationship.

4 ansfer and in situ production of HO(*) using structure-activity relationships.

5 cromolar concentrations, showing interesting structure-activity relationships.

6 drugs) provides a powerful tool for studying structure-activity relationships.

7 along with their high-resolution co-crystal structure-activity relationships.

8 s and docking studies explained the observed structure-activity relationships.

9 ates for evaluation and the establishment of structure-activity relationships.

10 ng rapid derivatization for investigation of structure-activity relationships.

11 ally modified this scaffold and explored its structure-activity relationships.

12 ic kidney) cell line], and a set of valuable structure-activity relationships.

13 2B37 that will aid in the elucidation of new structure-activity relationships.

14 omboids to gain insight into their secondary structure-activity relationships.

15 tility: assessing dataset overlap and mining structure-activity relationships.

16 CLC, SISO, and HT29) in order to investigate structure-activity relationships.

17 s is essential to gain in-depth insight into structure-activity relationships.

18 ructural features in order to deduce crucial structure-activity relationships.

19 etics relationships next to more traditional structure-activity relationships.

20 eening would have the advantage of providing structure-activity relationships against hundreds of tar

21 1 muM at all three subtypes, this elaborate structure-activity relationship also identified analogue

22 Structure-activity relationship analyses demonstrate tha

23 We report the structure-activity relationship analyses of 17 linear li

24 rovided on the basis of mutagenesis studies, structure-activity relationship analyses with newly desi

25 in binding contributions allows for improved structure-activity relationship analysis and structure-b

26 The structure-activity relationship analysis provided the st

27 Structure-activity relationship analysis revealed that h

28 Structure-activity relationship analysis revealed that t

29 of linear and cyclic peptides and performing structure-activity relationship analysis, we designed cy

30 to design the inhibitors and facilitate the structure-activity relationship analysis.

31 silico screening techniques and discuss the structure-activity relationship and pharmacological pote

32 e presented results provide insight into the structure-activity relationship and promote a rational s

33 mation on chemokine receptors with extensive structure-activity relationship and site-directed mutage

34 of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical o

35 Structure-activity relationships and a high resolution X

36 Clear structure-activity relationships and a structural model

37 serve as the basis for continued analysis of structure-activity relationships and drug development ef

38 We established structure-activity relationships and focused our attenti

39 ta are critical components for understanding structure-activity relationships and for design of new a

40 The structure-activity relationships and hit-to-lead optimiz

41 sites, an essential step toward establishing structure-activity relationships and promoting rational

42 tent inhibitors in order to understand their structure-activity relationships and provide a framework

43 We delineate here ELA's structure-activity relationships and report the identifi

44 These studies led to interesting structure-activity relationships and the identification

45 nt of defined glycans is key to establishing structure-activity relationships and thereby progress in

46 Furthermore, we have uncovered structure-activity relationships and used alternate conf

47 These compounds possess defined structure-activity relationships and we present crystal

48 ompound class, we have uncovered interesting structure-activity relationships and were able to decrea

49 In summary, we present synthesis, structure-activity relationship, and efficacy in gliobla

50 Design synthesis, structure-activity relationships, and binding mode of qu

51 abeling, NMR spectroscopy, kinetic modeling, structure-activity relationships, and new reaction devel

52 r Evaluating Risk (ASTER) QSAR (quantitative structure activity relationship) application, and the EP

53 hem was selected as a hit and optimized by a structure-activity relationship approach, leading to the

54 rs, the hit-to-lead studies, and the emerged structure-activity relationship are described.

55 The structure-activity relationship around 6 is described an

56 we present initial optimization efforts and structure-activity relationships around one of those pre

57 In an effort to understand the structure-activity relationships around these compounds,

58 Herein, we conduct a detailed structure-activity relationship assessment of adenine-ba

59 We explored the structure-activity relationship at 5HT2Rs and modeled re

60 te the applicability of Janus-GDs to dissect structure-activity relationships between programmable ce

61 builds on the important work in quantitative structure-activity relationships by linking toxicologica

62 Results from this study demonstrate that structure-activity relationships can be used to design n

63 They do, however, exhibit clear structure-activity relationships, consistent across both

64 Structure-activity relationships could be driven and res

65 The structure activity relationship data were analysed using

66 Structure-activity relationship data and ligand deconstr

67 Detailed structure-activity relationship data are shown.

68 timization, ADME profile evaluation, and the structure-activity relationship data raised for each com

69 e provides a mechanistic explanation for the structure-activity relationship data, most notably the l

70 consistent with previously reported and new structure-activity relationship data.

71 Notably, specific structure-activity relationships demonstrated the import

72 The structure-activity relationships derived from these resu

73 Structure-activity relationships detail how in a logical

74 ave implications in antibody engineering and structure/activity relationship determination in a varie

75 Structure-activity relationship, docking and mutagenesis

76 enon are discussed in terms of concepts like structure-activity relationships, donor-acceptor interac

77 Structure-activity relationship efforts led to generatio

78 cts in vivo Structural optimization based on structure-activity relationships enabled the chemical sy

79 Structure activity relationships established that the 1'

80 We describe herein further structure-activity relationship exploration of this seri

81 ug flupirtine was synthesized to determine a structure-activity relationship for neuroprotective acti

82 RD interactions and developed a quantitative structure-activity relationship for predicting their bin

83 The first structure-activity relationship for this antibacterial s

84 molecular level understanding and regions of structure-activity relationship for triterpene maslinic

85 Structure-activity relationships for a series of 3-pheno

86 We describe herein the structure-activity relationships for analogs of 3 with e

87 minophenyl-1,3,5-triazine analogs elucidated structure-activity relationships for CFTR activation and

88 This investigation highlights novel structure-activity relationships for future chemotherape

89 Structure-activity relationships for inhibition of erbB1

90 Our results document structure-activity relationships for lead-like small mol

91 al chemistry campaign in order to define the structure-activity relationships for one of the released

92 analysis of intermediates revealed distinct structure-activity relationships for respective target p

93 hydrophilic substituents revealed important structure-activity relationships for their use in photod

94 Herein we report the structure-activity relationships from identification of

95 Structure-activity relationships have established severa

96 ione, were utilized to gain insight into the structure-activity relationships in binding to COMT and

97 tance determinants and in vitro experimental structure-activity relationships in both P. falciparum a

98 derstanding their roles to elucidate surface structure-activity relationships in optical (solar cells

99 this study, we endeavored to reveal detailed structure-activity relationships in this loop to advance

100 h differing physiochemical properties reveal structure-activity relationships in which PR characteris

101 The structure-activity relationship indicates that the N-4-m

102 gh-throughput screening campaign and through structure-activity relationship investigations, we have

103 Structure-activity relationship, lead optimization, in s

104 Structure-activity relationships leading to the discover

105 pace and accelerate the investigation of key structure-activity relationships, leading to the develop

106 Exploration of the structure-activity relationship led to compounds display

107 Structure-activity relationships led to the discovery of

108 Clues from the structure-activity relationships lining up the antituber

109 h known sweetness values, a new quantitative structure-activity relationship model for sweetness pred

110 e of the present study is to develop an SAR (Structure-Activity Relationship) model that can be used

111 ivo and in vitro bioassays, and quantitative structure activity relationship modeling.

112 al elaboration combined with 3D-quantitative structure-activity relationship modeling yielded analogu

113 Quantitative structure-activity relationship models and docking appro

114 The structure-activity relationships observed in this study

115 The design, synthesis, and structure-activity relationship of 1-phenoxy-2-aminoinda

116 lar modeling, we synthesized and studied the structure-activity relationship of 40 compounds against

117 We here report the synthesis and structure-activity relationship of 71 analogues.

118 hlights the difficulty in characterizing the structure-activity relationship of a chemical series in

119 The structure-activity relationship of C11 was investigated

120 nolic compounds was studied to determine the structure-activity relationship of phenolic compounds on

121 The new analogues provide a comprehensive structure-activity relationship of the benzene-sulfonami

122 Based on the structure-activity relationship of these compounds, we s

123 emistry exploration, we established a robust structure-activity relationship of these two scaffolds,

124 We extended the structure-activity relationship of this series with smal

125 We report the design, synthesis, and structure-activity relationships of 3-(piperidin-4-ylmet

126 By analyzing the structure-activity relationships of 35 chemical derivati

127 Herein, we report the discovery and structure-activity relationships of 5-substituted-2-[(3,

128 Here, we describe the structure-activity relationships of a series of halogena

129 Herein, structure-activity relationships of a series of imidazol

130 Here we explored structure-activity relationships of a series of pyrazolo

131 rt the synthesis, biological evaluation, and structure-activity relationships of a small molecules li

132 ctions and binding site solvation to develop structure-activity relationships of beta2 ligand binding

133 The provided insights and framework for structure-activity relationships of bivalent degraders a

134 ar activity of phosphinophosphonates, reveal structure-activity relationships of butyrophilin ligands

135 We describe here the structure-activity relationships of highly potent S1P1 m

136 ategy that allows us to promptly explore the structure-activity relationships of isoxazole-containing

137 The structure-activity relationships of MPC6 variants were e

138 An important insight into the structure-activity relationships of NirE has been reveal

139 We report the design, synthesis, and structure-activity relationships of novel dual-target co

140 ography is the prime method for establishing structure-activity relationships of pharmaceutically rel

141 Herein, the structure-activity relationships of selected thiosemicar

142 f this Perspective is to review the reported structure-activity relationships of the different series

143 This is the first study to report structure-activity relationships of the maturation inhib

144 The structure-activity relationships of the new compounds ar

145 The current study set out to understand the structure-activity relationships of these targets in Mtb

146 The comprehensive structure-activity relationships of triantennary GalNAc

147 Here, we analyzed the structure-activity-relationships of ASO-protein interact

148 macophores and systematic exploration of the structure-activity relationship on both targets produced

149 This study expands the structure-activity relationships on our original series

150 by high-throughput screening, and subsequent structure-activity relationship optimization allowed gen

151 Through structure-activity relationship optimization, a 3-(N-pip

152 were then used in mechanistic (quantitative) structure-activity relationship ((Q)SAR) analysis to sho

153 rometry (LC-MS/MS), qualitative/quantitative structure activity relationship (QSAR) and confirmatory

154 A quantitative structure-activity relationship (QSAR) analysis revealed

155 s targeting TTR, we developed a quantitative structure-activity relationship (QSAR) classification mo

156 relative biodegradabilities and quantitative structure-activity relationship (QSAR) model outputs.

157 utilizes a battery of in-house quantitative structure-activity relationship (QSAR) models to generat

158 Quantitative structure-activity relationship (QSAR) models were devel

159 employ toxicity estimates from quantitative structure-activity relationship (QSAR) models.

160 nding assays to assess OASIS, a quantitative structure-activity relationship (QSAR) platform covering

161 correlations gave satisfactory quantitative structure-activity relationships (QSARs), but they impro

162 ein-mRNA complexes, drawing conclusions from structure-activity relationships remains a challenge.

163 efinement of this chemotype for establishing structure-activity relationship resulted in the identifi

164 hich was subjected to systematic analysis of structure-activity relationships, resulting in the devel

165 A detailed structure-activity relationship revealed that the most a

166 Structure-activity relationships revealed that the prese

167 -hydroxysuccinimide inhibitors grounded upon structure activity relationship (SAR) fundamentals.

168 es offer the promise of rapid exploration of structure activity relationships (SAR), the generation o

169 Structure-activity relationship (SAR) analysis led to th

170 Qualitative structure-activity relationship (SAR) analysis revealed

171 volution of our medicinal chemistry program, structure-activity relationship (SAR) analysis, as well

172 Through structure-activity relationship (SAR) analysis, we obtai

173 DPA), several libraries were synthesized for structure-activity relationship (SAR) analysis.

174 This review is focused on structure-activity relationship (SAR) and structure-affi

175 Structure-activity relationship (SAR) concerning primari

176 hia coli SSO, their development was based on structure-activity relationship (SAR) data generated in

177 iodistribution determination, a PET-specific structure-activity relationship (SAR) effort, and specif

178 Additional structure-activity relationship (SAR) efforts aimed both

179 Here, we describe structure-activity relationship (SAR) efforts that resul

180 uggesting that it may be amenable to further structure-activity relationship (SAR) for identifying RN

181 In this study, we have delineated the structure-activity relationship (SAR) for these differen

182 for the kappa opioid receptor (KOR), and its structure-activity relationship (SAR) has been extensive

183 ational framework to follow the evolution of structure-activity relationship (SAR) information over a

184 We will describe structure-activity relationship (SAR) leading to the dis

185 Exploration of this structure-activity relationship (SAR) led to the identif

186 C-H abstraction, not currently considered in structure-activity relationship (SAR) models.

187 We report here the synthesis and structure-activity relationship (SAR) of a novel series

188 We assessed the structure-activity relationship (SAR) of Tg for SPCA1a b

189 nide arterolane (OZ277), we now describe the structure-activity relationship (SAR) of the antimalaria

190 By use of this information, the structure-activity relationship (SAR) of the quinolinol-

191 To probe the structure-activity relationship (SAR) of the scaffold 1,

192 We explored the structure-activity relationship (SAR) of this compound s

193 like inhibitor of type I PRMTs, we conducted structure-activity relationship (SAR) studies and explor

194 promoting HSCs expansion, and then performed structure-activity relationship (SAR) studies by synthes

195 Further structure-activity relationship (SAR) studies identified

196 Further structure-activity relationship (SAR) studies led to 8,

197 Structure-activity relationship (SAR) studies of 6 demon

198 the lengthy synthetic routes and the lack of structure-activity relationship (SAR) studies of these c

199 o be either relatively toxic or ineffective, structure-activity relationship (SAR) studies on cinnami

200 Further structure-activity relationship (SAR) studies on the rec

201 e synthesis of 36 derivatives and subsequent structure-activity relationship (SAR) studies provided i

202 Structure-activity relationship (SAR) studies resulted i

203 Structure-activity relationship (SAR) studies were there

204 outer vestibule of NaV through a systematic structure-activity relationship (SAR) study involving th

205 A structure-activity relationship (SAR) study showed that,

206 inhibitors, there has not been a systematic structure-activity relationship (SAR) study to investiga

207 ffinity at all four subtypes, we conducted a structure-activity relationship (SAR) study to probe lig

208 Following a quantitative structure-activity relationship (SAR) study, 25 disulfid

209 From this structure-activity relationship (SAR) study, novel irrev

210 A pilot in vivo structure-activity relationship (SAR) was explored, eval

211 H1299 and Bel-7402 cell lines coupled with a structure-activity relationship (SAR) were investigated.

212 The synthesis, structure-activity relationship (SAR), and evolution of

213 f results that provide explicit chemistry or structure-activity relationship (SAR), or appear to be o

214 le infection assay to derive a comprehensive structure-activity relationship (SAR).

215 positive and Gram-negative bacteria revealed structure-activity relationships (SAR) and identificatio

216 This article details the structure-activity relationships (SAR) leading to a nove

217 Herein, we report the structure-activity relationships (SAR) of a previously r

218 n, the results help to further elucidate the structure-activity relationships (SAR) of the resulting

219 f bacterial isolates were identified through structure-activity relationships (SAR) studies.

220 Here, we explore the structure-activity relationships (SAR) through the desig

221 novel congeners, as well as their pronounced structure-activity relationships (SAR) with respect to i

222 wed the elucidation of previously unexplored structure-activity relationships (SAR) within the Mitrag

223 innovative and efficient approach to uncover structure-activity relationships (SARs) and guide drug d

224 en to PBD-containing ADCs, and explores both structure-activity relationships (SARs) and the biology

225 Structure-activity relationships (SARs) at each of the s

226 Furthermore, a study of structure-activity relationships (SARs) disclosed proper

227 ange of activity and developed comprehensive structure-activity relationships (SARs) for NNMT inhibit

228 based transactivation measurements delineate structure-activity relationships (SARs) for PPARdelta-se

229 Yet, no structure-activity relationships (SARs) have been identi

230 tural products and analogues that expand the structure-activity relationships (SARs) in this family.

231 Specifically, extensive structure-activity relationships (SARs) investigations w

232 This article will detail the structure-activity relationships (SARs) leading to a nov

233 The focus of this study was to generate structure-activity relationships (SARs) of INSL5 and use

234 ptins and a comprehensive examination of the structure-activity relationships (SARs) of this new clas

235 udies culminated in useful and path-pointing structure-activity relationships (SARs) that provide gui

236 Structure-activity relationships (SARs) were steep.

237 Close inspection of the structure-activity-relationships (SARs) of the phenylthi

238 Exploration of structure-activity relationships showed that inhibitors

239 esolution to rationalize previously reported structure activity relationship studies.

240 ackbone-cyclized peptides to quickly perform structure-activity relationship studies for optimizing p

241 A combination of molecular modeling and structure-activity relationship studies has been used to

242 Structure-activity relationship studies have now been pe

243 Initial structure-activity relationship studies have resulted in

244 Initial structure-activity relationship studies identified N-(2-

245 ual TLR7/TLR8-active compounds, we undertook structure-activity relationship studies in pyrimidine 2,

246 Concomitant structure-activity relationship studies indicated very s

247 Systematic structure-activity relationship studies led to the ident

248 Here, we report preliminary structure-activity relationship studies of a previously

249 Herein, we report the design, synthesis, and structure-activity relationship studies of guanidine-bas

250 Our initial structure-activity relationship studies on 7-methoxy-4-m

251 ults are useful to interpret future in vitro structure-activity relationship studies on these natural

252 Kinetic, computational, and structure-activity relationship studies provide evidence

253 Conducted analog synthesis and structure-activity relationship studies provided analogs

254 Initial structure-activity relationship studies resulted in comp

255 Structure-activity relationship studies revealed several

256 Structure-activity relationship studies revealed that th

257 similarities with known NSAIDs, we conducted structure-activity relationship studies that led to the

258 rein, we describe the design, synthesis, and structure-activity relationship studies that led to the

259 was synthesized and subjected to preliminary structure-activity relationship studies to generate a fo

260 for developing TDP2 inhibitors and encourage structure-activity relationship studies to shed more lig

261 it a merged sEH/PPARgamma pharmacophore, and structure-activity relationship studies were performed o

262 on of quinoxaline-derived molecules based on structure-activity relationship studies, which led previ

263 ent interesting stereoisomeric analogues for structure-activity relationship studies.

264 ators with outstanding potential for further structure-activity relationship studies.

265 esis of well-defined HS oligosaccharides for structure-activity relationship studies.

266 have now facilitated mechanism of action and structure-activity relationship studies.

267 nantio- and diastereoselective synthesis and structure-activity relationship studies.

268 The structure-activity relationships studies strengthen the

269 Herein, we report a structure-activity relationship study for perhydrophenan

270 s of ten analogues, which provided the first structure-activity relationship study for this class of

271 A structure-activity relationship study led to the design

272 Herein, a truncation structure-activity relationship study of chimeric agouti

273 amine as a pure TLR8 agonist, and a detailed structure-activity relationship study of this chemotype

274 We have completed a full structure-activity relationship study on 4(1H)-quinolone

275 A structure-activity relationship study revealed that modi

276 A structure-activity relationship study showed that the ch

277 is prompted us to subject 1a to an elaborate structure-activity relationship study through the purcha

278 Herein, through a structure-activity relationship study, we developed deri

279 Here, we present a well-defined structure-activity relationship study, which rationalize

280 ith medium isoform selectivity in a detailed structure-activity relationship study.

281 Reported here is a structure/activity relationship study of position Ser(84

282 ces, and based on previous information about structure-activity relationships, ten sequences were syn

283 profile similarity across the assays reveals structure-activity relationships that are useful for the

284 enocarcinoma cells generated target-agnostic structure-activity relationships that biased subsequent

285 cused kinetics experiments identify specific structure-activity relationships that illustrate the imp

286 ed investigations enabled the development of structure-activity relationships that ultimately led to

287 d in terms of their inhibitory potencies and structure-activity relationships through hit expansion g

288 mechanism of action, inhibition profile, and structure-activity relationships to provide insight into

289 itivity, and sought to establish informative structure-activity relationships, using electrophysiolog

290 Further structure-activity relationship, UV spectra, and structu

291 To understand thiocillin's structure-activity relationship, we generated a site-sat

292 To explore structure-activity relationships, we obtained natural an

293 nsive chemical synthesis and analysis of the structure-activity relationship were performed.

294 Structure-activity relationships were afforded for the c

295 Structure-activity relationships were established, and m

296 Structure-activity relationships were investigated using

297 Structure-activity relationships were investigated, with

298 ty relationship studies indicated very steep structure-activity relationships, which steer the ligand

299 Erasin was analyzed by the investigation of structure-activity relationships, which was facilitated

300 Structure-activity relationships within the 1,4-dihydrop